Pragmatic Approaches to Capture and Ascertainment of Clinical Trial Endpoints
捕捉和确定临床试验终点的务实方法
基本信息
- 批准号:10846657
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-01 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:Acute respiratory failureAdverse reactionsAlgorithmsArrhythmiaAspirinAsthmaBell PalsyCardiopulmonaryCardiovascular systemCessation of lifeChronic BronchitisChronic Obstructive Pulmonary DiseaseClassificationClinicalClinical ResearchClinical TrialsComputerized Medical RecordConduct Clinical TrialsCongestive Heart FailureConsumptionDataData SourcesDatabasesDoseEFRACEcosystemEncephalitisEnrollmentEventFaceGuillain Barré SyndromeHealthcare SystemsHeart failureHospitalizationLinkLungMedical RecordsMethodologyMethodsMyelitisMyocardial InfarctionNational Heart, Lung, and Blood InstituteOptic NeuritisOutcomeParticipantPatient CarePatientsPhase IV Clinical TrialsPhenotypePhysiciansPneumoniaPositioning AttributePragmatic clinical trialPulmonary EmbolismResearch PersonnelSingle-Payer SystemSiteSyndromeTelephoneTestingTimeToxic Epidermal NecrolysisUnited States Department of Veterans AffairsVaccinesVeteransVeterans Health Administrationacute coronary syndromeadjudicationcerebrovascularclinical careclinical databasecosteffectiveness trialelectronic medical record systemexperienceimprovedinfluenza virus vaccineinnovationmortalitypatient orientedpreservationseasonal influenza
项目摘要
Background and Significance:
Pragmatic approaches to the conduct of clinical trials would markedly reduce the burden on patients and the
clinical research ecosystem. Centralized capture and ascertainment of events is a major pragmatic approach
to replace local event capture and event adjudication by independent committees. An ongoing phase 4 clinical
trial sponsored by the National Heart, Lung, and Blood Institute, INfluenza Vaccine to Effectively Stop
CardioThoracic Events and Decompensated heart failure (INVESTED), in which the Veterans Affairs (VA)
Network of 34 sites led by the PI is participating, offers an ideal opportunity to develop appropriate
methodology to improve electronic medical record (EMR)-based centralized strategies for endpoint capture
and to compare central versus traditional event capture methodology.
We aim to test the hypothesis that centralized endpoint capture strategies are comparable to traditional
methods of event ascertainment utilizing the following specific aims:
Specific Aim 1. Develop algorithms for capture of major clinical trial endpoints.
We will develop methodology to capture following clinical trial endpoints from the national VA databases: all-
cause mortality, cardiovascular (CV) death, cardiopulmonary hospitalizations (CV -heart failure,
cerebrovascular events, myocardial infarction/acute coronary syndrome, arrhythmias; and pulmonary -
pneumonia, chronic obstructive pulmonary disease/chronic bronchitis, pulmonary embolism, asthma, acute
respiratory failure), and adverse reaction to vaccine (Guillain-Barre syndrome, Bell's palsy,
encephalitis/myelitis, optic neuritis, Steven-Johnson syndrome, toxic epidermal necrolysis), of enrolled
veterans by central methods. For event capture, we will identify endpoints from multiple VA and non-VA data
sources and use an iterative method to refine algorithms and will test validity of algorithms by independent
physician review and adjudication of medical records.
Specific Aim 2. Compare the event capture rate between central and traditional methods of endpoint
capture and ascertainment.
Outcomes (projected) and Anticipated impact:
We will compare event capture rates of central and traditional methods for each of the major clinical trial
endpoints described in Specific Aim 1 at the event level during each consecutive influenza season and over
the entire trial period.
We will develop methods to accurately capture major clinical trial endpoints using algorithms that will be easily
applicable to any EMR system. We also expect to find that EMR based event capture strategies are non-
inferior to traditional methods. This project will also provide significant new data about how to streamline
central approaches to achieve real-time capture and ascertainment of endpoints in clinical trials. This project is
highly significant since it will develop centralized event capture methods that will reduce the costs of
conducting clinical trials as well as the burden on patients, investigators, and the clinical research ecosystem,
and make the VA a world leader in innovative approaches to clinical trials.
背景和意义:
采取务实的方法进行临床试验将显著减轻患者的负担,
临床研究生态系统。集中捕获和确定事件是一种主要的实用方法
取代由独立委员会进行的当地事件采集和事件裁定。正在进行的4期临床试验
由国家心肺血液研究所赞助的一项试验,流感疫苗有效阻止
胸事件和失代偿性心力衰竭(INVESTED),其中退伍军人事务部(VA)
由PI领导的34个研究中心组成的网络正在参与,为制定适当的
改进基于电子病历(EMR)的集中式端点捕获策略的方法
并比较中心事件捕获方法与传统事件捕获方法。
我们的目标是测试集中式端点捕获策略与传统端点捕获策略相比的假设。
利用以下具体目标的事件查明方法:
具体目标1。开发用于捕获主要临床试验终点的算法。
我们将开发从国家VA数据库中获取以下临床试验终点的方法:所有-
原因死亡率、心血管(CV)死亡、心肺住院(CV -心力衰竭,
脑血管事件、心肌梗死/急性冠状动脉综合征、心律失常;以及肺-
肺炎、慢性阻塞性肺病/慢性支气管炎、肺栓塞、哮喘、急性
呼吸衰竭)和对疫苗的不良反应(格林-巴利综合征,贝尔麻痹,
脑炎/肌炎、视神经炎、Steven-Johnson综合征、中毒性表皮坏死松解症),
用中央方法。对于事件采集,我们将从多个VA和非VA数据中识别终点
来源,并使用迭代方法来完善算法,并将通过独立的
医生对医疗记录的审查和裁定。
具体目标2。比较中心和传统终点方法的事件捕获率
捕获和确认。
成果(预计)和预期影响:
我们将比较每项主要临床试验的中心方法和传统方法的事件捕获率
在每个连续流感季节及以上的事件水平上,具体目标1中描述的终点
整个审判期间。
我们将开发使用算法准确捕获主要临床试验终点的方法,
适用于任何电子病历系统。我们还希望发现,基于EMR的事件捕获策略是非
比传统方法差。该项目还将提供有关如何简化
在临床试验中实现实时捕获和确定终点的中心方法。这个项目是
非常重要,因为它将开发集中的事件捕获方法,
开展临床试验以及患者、研究者和临床研究生态系统的负担,
并使VA成为临床试验创新方法的世界领导者。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jacob Joseph其他文献
Jacob Joseph的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jacob Joseph', 18)}}的其他基金
Treatment of Veterans with Heart Failure with Reduced Ejection Fraction with Probenecid
用丙磺舒治疗射血分数降低的心力衰竭退伍军人
- 批准号:
10415824 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Treatment of Veterans with Heart Failure with Reduced Ejection Fraction with Probenecid
用丙磺舒治疗射血分数降低的心力衰竭退伍军人
- 批准号:
10002646 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Treatment of Veterans with Heart Failure with Reduced Ejection Fraction with Probenecid
用丙磺舒治疗射血分数降低的心力衰竭退伍军人
- 批准号:
10578647 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Pragmatic Approaches to Capture and Ascertainment of Clinical Trial Endpoints
捕捉和确定临床试验终点的务实方法
- 批准号:
10413948 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Pragmatic Approaches to Capture and Ascertainment of Clinical Trial Endpoints
捕捉和确定临床试验终点的务实方法
- 批准号:
10292882 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Pragmatic Approaches to Capture and Ascertainment of Clinical Trial Endpoints
捕捉和确定临床试验终点的务实方法
- 批准号:
10844177 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Selenium, Glutathione Peroxidase-1, and Homocysteine-induced Cardiac Remodeling
硒、谷胱甘肽过氧化物酶 1 和同型半胱氨酸诱导的心脏重塑
- 批准号:
7470473 - 财政年份:2008
- 资助金额:
-- - 项目类别:
Selenium, Glutathione Peroxidase-1, and Homocysteine-induced Cardiac Remodeling
硒、谷胱甘肽过氧化物酶 1 和同型半胱氨酸诱导的心脏重塑
- 批准号:
7587952 - 财政年份:2008
- 资助金额:
-- - 项目类别:
Selenium, Glutathione Peroxidase-1, and Homocysteine-induced Cardiac Remodeling
硒、谷胱甘肽过氧化物酶 1 和同型半胱氨酸诱导的心脏重塑
- 批准号:
8195301 - 财政年份:2008
- 资助金额:
-- - 项目类别:
相似海外基金
A personalised approach to manage adverse reactions to CFTR modulator therapy in patients with cystic fibrosis
治疗囊性纤维化患者 CFTR 调节剂治疗不良反应的个性化方法
- 批准号:
MR/X00094X/1 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Research Grant
Mechanistic study of sulfa drug-induced severe cutaneous adverse reactions by focusing on HLA-A*11:01
以HLA-A*为重点的磺胺类药物致严重皮肤不良反应机制研究11:01
- 批准号:
22K06738 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identifying genetic polymorphisms and elucidating polygenic architecture associated with adverse reactions due to rituximab
识别遗传多态性并阐明与利妥昔单抗不良反应相关的多基因结构
- 批准号:
22K15910 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Severe Cutaneous Adverse Reactions Following Outpatient Antibiotic Therapy: A Population-based Study
门诊抗生素治疗后的严重皮肤不良反应:一项基于人群的研究
- 批准号:
449379 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Studentship Programs
Significance of gamma-chain in severe cutaneous adverse reactions
伽马链在严重皮肤不良反应中的意义
- 批准号:
19K17779 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Historical sociology of adverse reactions related to vaccination in Japan
日本疫苗接种不良反应的历史社会学
- 批准号:
18K00267 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
SEARCH (active Surveillance and Evaluation of Adverse Reactions in Canadian Healthcare) & PREVENT (Pharmacogenomics of Adverse Reaction EVEnts National Team)
SEARCH(加拿大医疗保健不良反应的主动监测和评估)
- 批准号:
379425 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Operating Grants
IGF::OT::IGF SBIR Phase II: Topic 338 - Predictive Biomarkers of Adverse Reactions to Prostrate Cancer Radiotherapy
IGF::OT::IGF SBIR II 期:主题 338 - 前列腺癌放射治疗不良反应的预测生物标志物
- 批准号:
9576448 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Development of in silico prediction method for idiosyncratic adverse reactions associated with HLA genotypes
与 HLA 基因型相关的特殊不良反应的计算机预测方法的开发
- 批准号:
16K15156 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Characterising the Immune Response to Drugs That Cause Idiosyncratic Adverse Reactions
表征对引起特殊不良反应的药物的免疫反应
- 批准号:
367156 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Studentship Programs